FENC vs. LENZ, REPL, VIR, IOVA, IMTX, AVXL, SANA, AUTL, TSHA, and RLAY
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include LENZ Therapeutics (LENZ), Replimune Group (REPL), Vir Biotechnology (VIR), Iovance Biotherapeutics (IOVA), Immatics (IMTX), Anavex Life Sciences (AVXL), Sana Biotechnology (SANA), Autolus Therapeutics (AUTL), Taysha Gene Therapies (TSHA), and Relay Therapeutics (RLAY). These companies are all part of the "biological products, except diagnostic" industry.
Fennec Pharmaceuticals vs. Its Competitors
LENZ Therapeutics (NASDAQ:LENZ) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.
LENZ Therapeutics has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Fennec Pharmaceuticals' return on equity of -53.38% beat LENZ Therapeutics' return on equity.
LENZ Therapeutics has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.
54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. 6.9% of LENZ Therapeutics shares are owned by insiders. Comparatively, 11.8% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Fennec Pharmaceuticals received 189 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 66.89% of users gave Fennec Pharmaceuticals an outperform vote.
Fennec Pharmaceuticals has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, LENZ Therapeutics and LENZ Therapeutics both had 5 articles in the media. LENZ Therapeutics' average media sentiment score of 1.10 beat Fennec Pharmaceuticals' score of 0.90 indicating that LENZ Therapeutics is being referred to more favorably in the media.
LENZ Therapeutics presently has a consensus target price of $46.60, indicating a potential upside of 59.64%. Fennec Pharmaceuticals has a consensus target price of $13.00, indicating a potential upside of 59.41%. Given LENZ Therapeutics' higher probable upside, equities research analysts plainly believe LENZ Therapeutics is more favorable than Fennec Pharmaceuticals.
Summary
Fennec Pharmaceuticals beats LENZ Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:FENC) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy FENC Stock Free FENC Stock Alerts